Freddy A. Jimenez, SVP and General Counsel at Celldex Therapeutics ($CLDX), sold about $140 thousand worth of company shares in three open market transactions over the past year. His most recent sale occurred on December 4, 2025. These sales rank 9,077th among 11,678 individual insiders, far below the average of $8.6 million per seller and 6.4 transactions. Jimenez made no open market purchases in the last 365 days.
| Transaction Date | Company | Ticker | Insider Name | Title | Transaction Type | Security | Shares | Price | Shares Owned Following | Total Shares Outstanding | % of Owned | % of Outstanding |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Dec. 4, 2025 | Celldex Therapeutics, Inc. | $CLDX | Jimenez Freddy A. | SVP & GENERAL COUNSEL | S | Common Stock | 4166 | $29.10 | 30,796.0000 | 66,420 | 11.92% | 6.27% |
| Aug. 13, 2025 | Celldex Therapeutics, Inc. | $CLDX | Jimenez Freddy A. | SVP & GENERAL COUNSEL | S | Common Stock | 430 | $25.42 | 34,962.0000 | 66,392 | 1.21% | 0.65% |
| Aug. 13, 2025 | Celldex Therapeutics, Inc. | $CLDX | Jimenez Freddy A. | SVP & GENERAL COUNSEL | S | Common Stock | 341 | $23.95 | 35,392.0000 | 66,392 | 0.95% | 0.51% |
| June 5, 2025 | Celldex Therapeutics, Inc. | $CLDX | Jimenez Freddy A. | SVP & GENERAL COUNSEL | A | Incentive Stock Option (right to buy) | 75000 | $0.00 | 75,000.0000 | 66,383 | 9999.99% | 100.00% |
| June 13, 2024 | Celldex Therapeutics, Inc. | $CLDX | Jimenez Freddy A. | SVP & GENERAL COUNSEL | A | Incentive Stock Option (right to buy) | 75000 | $0.00 | 75,000.0000 | 58,871 | 9999.99% | 100.00% |
| June 5, 2024 | Celldex Therapeutics, Inc. | $CLDX | Jimenez Freddy A. | SVP & GENERAL COUNSEL | M | Incentive Stock Option (Right to Buy) | 9540 | $0.00 | 18,454.0000 | 58,871 | 34.08% | 16.21% |
| June 5, 2024 | Celldex Therapeutics, Inc. | $CLDX | Jimenez Freddy A. | SVP & GENERAL COUNSEL | M | Common Stock | 9540 | $10.38 | 35,464.0000 | 58,871 | 36.80% | 16.21% |
| June 3, 2024 | Celldex Therapeutics, Inc. | $CLDX | Jimenez Freddy A. | SVP & GENERAL COUNSEL | S | Common Stock | 8006 | $33.60 | 25,924.0000 | 58,871 | 23.60% | 13.60% |
| June 3, 2024 | Celldex Therapeutics, Inc. | $CLDX | Jimenez Freddy A. | SVP & GENERAL COUNSEL | M | Incentive Stock Option (Right to Buy) | 8006 | $0.00 | 27,994.0000 | 58,871 | 22.24% | 13.60% |
| June 3, 2024 | Celldex Therapeutics, Inc. | $CLDX | Jimenez Freddy A. | SVP & GENERAL COUNSEL | M | Common Stock | 8006 | $10.38 | 33,930.0000 | 58,871 | 30.88% | 13.60% |
| Feb. 13, 2024 | Celldex Therapeutics, Inc. | $CLDX | Jimenez Freddy A. | SVP & GENERAL COUNSEL | M | Common Stock | 20000 | $2.78 | 25,924.0000 | 48,449,000 | 337.61% | 0.04% |
| Feb. 13, 2024 | Celldex Therapeutics, Inc. | $CLDX | Jimenez Freddy A. | SVP & GENERAL COUNSEL | M | Incentive Stock Option (Right to Buy) | 4166 | $0.00 | 0.0000 | 48,449,000 | 100.00% | 0.01% |
| Feb. 13, 2024 | Celldex Therapeutics, Inc. | $CLDX | Jimenez Freddy A. | SVP & GENERAL COUNSEL | M | Incentive Stock Option (Right to Buy) | 20000 | $0.00 | 0.0000 | 48,449,000 | 100.00% | 0.04% |
| Feb. 13, 2024 | Celldex Therapeutics, Inc. | $CLDX | Jimenez Freddy A. | SVP & GENERAL COUNSEL | M | Common Stock | 4166 | $9.02 | 5,924.0000 | 48,449,000 | 236.97% | 0.01% |
| June 15, 2023 | Celldex Therapeutics, Inc. | $CLDX | Jimenez Freddy A. | SVP & GENERAL COUNSEL | A | Incentive Stock Option (right to buy) | 74000 | $0.00 | 74,000.0000 | 47,214 | 9999.99% | 100.00% |